How Cellebrite’s New C-TEK Kit and Genesis Expansion Could Reframe Cellebrite DI (CLBT) Investors

Simply Wall St.08-31

In August 2026, Cellebrite DI Ltd. launched its rugged Cellebrite Tactical Extraction Kit (C-TEK) for real-time, in-field mobile forensics and expanded its AI-powered Genesis investigation platform to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2663001442?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","is_english":true,"pubTime":"2026-08-31 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663001442","market":"sg","top_or_hot":-1,"title":"How Cellebrite’s New C-TEK Kit and Genesis Expansion Could Reframe Cellebrite DI (CLBT) Investors","media":"Simply Wall St.","content":"<div>\n<p>In August 2026, Cellebrite DI Ltd. launched its rugged Cellebrite Tactical Extraction Kit (C-TEK) for real-time, in-field mobile forensics and expanded its AI-powered Genesis investigation platform to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/how-cellebrites-new-c-tek-kit-and-genesis-expansion-could-re\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Cellebrite’s New C-TEK Kit and Genesis Expansion Could Reframe Cellebrite DI (CLBT) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Cellebrite’s New C-TEK Kit and Genesis Expansion Could Reframe Cellebrite DI (CLBT) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-31 19:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/how-cellebrites-new-c-tek-kit-and-genesis-expansion-could-re><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In August 2026, Cellebrite DI Ltd. launched its rugged Cellebrite Tactical Extraction Kit (C-TEK) for real-time, in-field mobile forensics and expanded its AI-powered Genesis investigation platform to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/how-cellebrites-new-c-tek-kit-and-genesis-expansion-could-re\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTHR","symbol_name":"Vanguard Russell 3000 ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/how-cellebrites-new-c-tek-kit-and-genesis-expansion-could-re","article_id":"2663001442","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/how-cellebrites-new-c-tek-kit-and-genesis-expansion-could-re","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2663001442","pubTimestamp":1788175248,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In August 2026, Cellebrite DI Ltd. launched its rugged Cellebrite Tactical Extraction Kit (C-TEK) for real-time, in-field mobile forensics and expanded its AI-powered Genesis investigation platform to additional global public sector and enterprise customers.\nTogether, these moves deepen Cellebrite’s reach into defense and corporate investigations, signaling a push to bring its digital intelligence tools closer to the edge of operations worldwide.\nWe’ll now explore how extending Genesis into...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTHR":"Vanguard Russell 3000 ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","AGIX":"通用人工智能 ETF-AGIX","DAT":"ProShares Big Data Refiners ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","ISBC":"投资者银行","BK4211":"区域性银行","CLBT":"Cellebrite","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4023":"应用软件","BK4613":"AI应用软件","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"Cellebrite 的新 C-TEK 套件和 Genesis 扩展如何重塑 Cellebrite DI (CLBT) 投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTHR":0.62,"QTOC":0.62,"AIPO":0.72,"AGIX":0.62,"ISBC":1.5,"DAT":0.6,"ARTY":0.62,"CLBT":1.5,"CHAT":0.62},"content_text":"In August 2026, Cellebrite DI Ltd. launched its rugged Cellebrite Tactical Extraction Kit (C-TEK) for real-time, in-field mobile forensics and expanded its AI-powered Genesis investigation platform to additional global public sector and enterprise customers. Together, these moves deepen Cellebrite’s reach into defense and corporate investigations, signaling a push to bring its digital intelligence tools closer to the edge of operations worldwide. We’ll now explore how extending Genesis into more markets and launching C-TEK in defense could reshape Cellebrite DI’s investment narrative. This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.AdvertisementCellebrite DI Investment Narrative RecapTo own Cellebrite DI, you need to believe its digital intelligence tools can keep attracting public sector, defense and corporate customers while it works through lumpier U.S. federal spending and rising privacy scrutiny. The Genesis expansion and new C TEK launch do not change those two near term swing factors in a material way, but they do highlight how much of the growth story now depends on broader adoption outside the core U.S. federal channel. The Genesis rollout to more global markets and enterprises feels most relevant here, because it directly addresses Cellebrite’s concentration risk in U.S. government contracts by widening the potential customer base. If Genesis adoption in Europe, Australia and corporate investigations accelerates as management hopes, it could gradually offset some of the revenue volatility tied to delayed U.S. federal budgets and give investors more confidence in the company’s recurring software profile. Yet while products like Genesis and C TEK expand Cellebrite’s reach, investors should be aware that growing privacy regulation and device security could still... Read the full narrative on Cellebrite DI (it's free!)Cellebrite DI's narrative projects $787.4 million revenue and $122.0 million earnings by 2029. This requires 15.3% yearly revenue growth and a $63.8 million earnings increase from $58.2 million today.Uncover how Cellebrite DI's forecasts yield a $15.36 fair value, a 28% upside to its current price.Exploring Other PerspectivesCLBT 1-Year Stock Price Chart By contrast, the most pessimistic analysts focus on how tougher encryption and privacy rules could cap growth, even as they still penciled in about US$803,300,000 of 2029 revenue and US$123,400,000 of earnings, reminding you that views on Cellebrite’s risk reward can differ sharply and may shift again as Genesis and C TEK play out.Explore 5 other fair value estimates on Cellebrite DI - why the stock might be worth just $14.41!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Cellebrite DI research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Cellebrite DI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cellebrite DI's overall financial health at a glance.Seeking Other Investments?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Find 45 companies with promising cash flow potential yet trading below their fair value.Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663001442","isCrawlerRequest":true}